Fennec Pharmaceuticals Inc.
FENC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001211583
In the last 90 days, Fennec Pharmaceuticals Inc. insiders filed 0 open-market purchases and 5 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $175.1M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Fennec Pharmaceuticals Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 96 | 2 | 90 | −4 |
| Shares | 15.5M | 1.07M | 16.2M | +1.73M (+12.0%) |
| Value | $119.6M | $8.23M | $99.6M | −$11.8M (−10.6%) |
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Fennec Pharmaceuticals Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Capital Management LLC | 897,144 | $5.52M | 0.00% |
| Vanguard Portfolio Management LLC | 168,473 | $1.04M | 0.00% |
| Cornerstone Capital, Inc. | 105,000 | $645.8K | 0.06% |
| Thompson Siegel & Walmsley LLC | 57,226 | $352.0K | 0.01% |
| Eleva Capital SAS | 53,234 | $327.4K | 0.10% |
| Vanguard Fiduciary Trust Co | 38,724 | $238.2K | 0.00% |
| Prelude Capital Management, LLC | 29,599 | $182.0K | 0.01% |
| Nano Cap New Millennium Growth Fund L P | 21,500 | $132.2K | 0.12% |
| Globeflex Capital L P | 18,343 | $112.8K | 0.02% |
| Engineers Gate Manager LP | 15,516 | $95.4K | 0.00% |
| Allworth Financial LP | 23 | $142 | 0.00% |
| Rothschild Investment LLC | 19 | $117 | 0.00% |
| MAI Capital Management | 18 | $111 | 0.00% |
| Wealth Preservation Advisors, LLC | 5 | $31 | 0.00% |
| IFP Advisors, Inc | 1 | $6 | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | $6 | 0.00% |
Sold out (20)
Institutions that held Fennec Pharmaceuticals Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Apis Capital Advisors, LLC | 204,000 | $1.57M |
| Marshall Wace, LLP | 127,693 | $983.2K |
| Stonepine Capital Management, LLC | 50,000 | $385.0K |
| Hillsdale Investment Management Inc. | 44,000 | $338.8K |
| Arrowstreet Capital, Limited Partnership | 32,460 | $249.9K |
| Acadian Asset Management LLC | 27,059 | $207.0K |
| Millennium Management LLC | 24,402 | $187.9K |
| Jane Street Group, LLC | 24,044 | $185.1K |
| Point72 Asset Management, L.P. | 21,298 | $164.0K |
| Renaissance Technologies LLC | 20,000 | $154.0K |
| Quadrature Capital Ltd | 14,761 | $113.7K |
| Lazard Asset Management LLC | 13,121 | $101.0K |
| Two Sigma Advisers, LP | 13,000 | $100.1K |
| Intech Investment Management LLC | 10,452 | $80.5K |
| Royal Bank of Canada | 2,467 | $19.0K |
| Amalgamated Bank | 736 | $6.00K |
| Quaker Wealth Management, LLC | 160 | $1.23K |
| National Bank of Canada | 97 | $747 |
| Advisor Group Holdings, Inc. | 75 | $577 |
| Optima Capital LLC | 63 | $485 |
Not filed for Q1 2026 yet (2)
Institutions that held Fennec Pharmaceuticals Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 1,067,651 | $8.22M |
| CIBC Private Wealth Group, LLC | 1,565 | $12.1K |